Clinical Scorecard: FDA Approval Targets Rare Kidney Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Focal segmental glomerulosclerosis without nephrotic syndrome |
| Key Mechanisms | Sparsentan targets endothelin A and angiotensin II receptors to reduce inflammation and scarring in the kidney |
| Target Population | Adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome |
| Care Setting | Specialist nephrology care with monitoring capabilities |
Key Highlights
- First FDA-approved pharmacologic treatment for focal segmental glomerulosclerosis without nephrotic syndrome
- Phase 3 DUPLEX trial showed 46% proteinuria reduction with sparsentan vs 30% with irbesartan at 108 weeks
- Sparsentan has a similar tolerability profile to irbesartan but requires liver function monitoring due to hepatotoxicity risk
Guideline-Based Recommendations
Diagnosis
- Confirm focal segmental glomerulosclerosis diagnosis by biopsy or genetic testing
- Assess proteinuria levels to determine eligibility
Management
- Initiate sparsentan to reduce proteinuria in patients aged 8 years and older without nephrotic syndrome
- Avoid sparsentan in pregnancy due to embryo-fetal toxicity
- Use restricted risk evaluation and mitigation strategy program for dispensing
Monitoring & Follow-up
- Assess liver function before treatment initiation and regularly during therapy
- Monitor blood pressure, potassium levels, and signs of peripheral edema
- Observe for adverse effects such as hypotension, dizziness, and anemia
Risks
- Hepatotoxicity requiring liver function monitoring
- Contraindicated in pregnancy due to embryo-fetal toxicity
- Potential adverse effects include hypotension, hyperkalemia, peripheral edema, dizziness, and anemia
Patient & Prescribing Data
Approximately 30,000 US patients with focal segmental glomerulosclerosis without nephrotic syndrome; broader population exceeds 100,000 including other indications
Sparsentan demonstrated superior proteinuria reduction compared to irbesartan with comparable tolerability in both adult and pediatric patients
Clinical Best Practices
- Confirm diagnosis with biopsy or genetic testing prior to treatment
- Perform baseline and ongoing liver function tests due to hepatotoxicity risk
- Educate patients on potential side effects and contraindications, especially pregnancy risks
- Use sparsentan within a restricted REMS program to ensure safe use
- Monitor renal function and proteinuria regularly to assess treatment efficacy
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
